A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

Eligibility Criteria

• 1. Have a PCED that is at least 2 weeks in duration and refractory to one or more conventional non-surgical standard of care (SOC) treatments
• 2. Have no clinical evidence of improvement in the PCED within 2 weeks prior to randomization despite the use of non-surgical SOC treatment
• 3. Subject must provide written informed consent (or assent)
• 4. Subjects with childbearing potential must be 1-year postmenopausal, surgically sterilized, or have a negative urine pregnancy test
• 1. Have a known ocular infection that is deemed to be active requiring therapeutic intervention
• 2. Present with a corneal surface defect in either eye that is directly attributed to an infectious etiology (bacterial, viral, fungal and/or protozoal) that has not fully resolved and/or treatment has not been completed
• 3. Present with evidence of corneal ulceration/melting involving the posterior third of the stroma and/or perforation in either eye
• 4. Have a blepharitis or meibomian gland disease in the study eye that is deemed to be clinically relevant and/or active
• 5. Have a history of ocular surgery or any ocular procedure(s) not meeting the designated washout time
• 6. Have any other ocular disease requiring topical ocular medication in the affected eye
• 7. Have a presence or history of any ocular or systemic disorder or condition that could interfere the safety or efficacy of the study treatment, or the interpretation of the study results
• 8. Have a known hypersensitivity to one of the components of the study or procedural medications (e.g., NEXAGON, fluorescein)
• 9. Participated in an interventional clinical drug or device trial within 28 days prior to Day 1
• 10. Use of the medications presented in the protocol that are prohibited in the study.